Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits

References

• Holbein ME, Berglund JP, Weatherwax K, et al. Access to investigational drugs: FDA expanded access programs or “Right-to-Try” legislation? Clin Transl Sci. 2015;8(5):526–532.
   PubMed Web of Science ®Google Scholar
• Saiyed MM, Ong PS, Chew L. Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Ther. 2017;42(3):251–258.
   PubMed Web of Science ®Google Scholar
• Code of federal regulations title 21. SERVICES DOHAH, editor; 2017. Available from: https://www.ecfr.gov/cgi-bin/text-idx?SID=3ee286332416f26a91d9e6d786a604ab&mc=true&tpl=/ecfrbrowse/Title21/21tab_02.tpl
   Google Scholar
• The history of Food and Drug Administration Agency. Available from: https://www.fda.gov/AboutFDA/WhatWeDo/History/default.htm
   Google Scholar
• 21 U.S.C. § 355. PLN-, 76 Stat. 780. [Safety and efficacy amendments to the Federal Food, Drug and Cosmetic Act]; 1962.
   Google Scholar
• 21 U.S.C. ch. 9 § 301 et seq. [Kefauver-Harris Amendment].
   Google Scholar
• Richey EA, Lyons EA, Nebeker JR, et al. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol. 2009;27(26):4398–4405.
   PubMed Web of Science ®Google Scholar
• Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000–2009. Clin Pharmacol Ther. 2011;89(2):183–188.
   PubMed Web of Science ®Google Scholar
• Lanthier ML, Sridhara R, Johnson JR, et al. Accelerated approval and oncology drug development timelines. J Clin Oncol. 2010;28(14):e226–e227. author reply e8.
   PubMed Web of Science ®Google Scholar
• Downing NS, Aminawung JA, Shah ND, et al. Regulatory review of novel therapeutics–comparison of three regulatory agencies. N Engl J Med. 2012;366(24):2284–2293.
   PubMed Web of Science ®Google Scholar
• Ns D, Ad Z, Ross JS. Regulatory review of new therapeutic agents - FDA versus EMA, 2011–2015. N Engl J Med. 2017;376(14):1386–1387.
   PubMed Web of Science ®Google Scholar
• FDA. Investigational new drug, antibiotic, and biologic drug product regulations: treatment use and sale. Fed Regist. 1987;52:19466–19467.
   Google Scholar
• Food and Drug Administration, HHS. Expanded access to investigational drugs for treatment use: final rule. Fed Regist. 2009;74(155):40900–40945.
   PubMedGoogle Scholar
• Trotta F, Leufkens HG, Schellens JH, et al. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice. J Clin Oncol. 2011;29(16):2266–2272.
   PubMed Web of Science ®Google Scholar
• FDA. Available from: https://blogs.fda.gov/fdavoice/index.php/2017/10/expanded-access-fda-describes-efforts-to-ease-application-process/
   Google Scholar
• DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther. 2001;69:297–307.
   PubMed Web of Science ®Google Scholar
• Martell RE, Sermer D, Getz K, et al. Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration. Oncologist. 2013;18(1):104–111.
   PubMed Web of Science ®Google Scholar
• Jarow JP, Lemery S, Bugin K, et al. Access of investigational drugs: the experience of the center of drug evaluation and research over a 10-year period. Ther Innov Regul Sci. 2016;50(6):705–709.
   PubMed Web of Science ®Google Scholar
• Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307–1316.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM. Initiative for molecular profiling and advanced cancer therapy and challenges in the implementation of precision medicine. Curr Probl Cancer. 2017;41(3):176–181.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012;18(22):6373–6383.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wen S, Hong DS, et al. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014;20(18):4827–4836.
   PubMed Web of Science ®Google Scholar
• FDA expanded access. Available from: https://www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/OOPDNewsArchive/UCM294794.pdf.
   Google Scholar
• Black L. Experimental breast cancer treatments and health insurance coverage. The Virtual Mentor. 2007;9(1):34–37.
   PubMedGoogle Scholar
• Falit BP, Gross CP. Access to experimental drugs for terminally ill patients. Jama. 2008;300(23):2793–2795.
   PubMed Web of Science ®Google Scholar
• Mack GS. Expanded access rules pose quandary for drug developers. Nat Biotechnol. 2009;27(10):871–872.
   PubMed Web of Science ®Google Scholar
• Kroll D 2014 March 12. Available from: https://www.forbes.com/sites/davidkroll/2014/03/12/why-everyone-has-a-stake-in-the-chimerix-drug-offered-to-josh-hardy-cmx001-brincidofovir/#6d2a1c7a40da
   Google Scholar
• Electronic Code of Federal Regulations, Part 314.510. US Food and Drug administration silver spring. MD US Food and Drug Administration; 2008. Available from: https://www.ecfr.gov/cgi-bin/text-idx?SID=3ee286332416f26a91d9e6d786a604ab&mc=true&tpl=/ecfrbrowse/Title21/21tab_02.tpl
   Google Scholar
• Jc D. Connecting patients with experimental drugs. Wall Street J. 2012, October22. Available from: https://www.wsj.com/articles/should-the-fda-relax-rules-on-compassionate-access-to-new-drugs-1491962521
   Google Scholar
• United States v. Rutherford, 442 U.S. 544; 1979.
   Google Scholar
• Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, 495 F.3d 695 (D.C. Cir. 2007).
   Google Scholar
• Dahl v. HEM Pharms, 7 F.3d 1399 (9th Cir. 1993).
   Google Scholar
• Mello MM, Joffe S. Compact versus contract–industry sponsors’ obligations to their research subjects. N Engl J Med. 2007;356(26):2737–2743.
   PubMed Web of Science ®Google Scholar
• Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005;352(9):895–904.
   PubMed Web of Science ®Google Scholar
• Freireich EJ, Kurzrock R. The role of investigational therapy in management of patients with advanced metastatic malignancy. J Clin Oncol. 2009;27(2):304–306.
   PubMed Web of Science ®Google Scholar
• Woloshin S, Schwartz LM, Welch HG. Patients and medical statistics. Interest, confidence, ability. J General Internal Med. 2005;20(11):996–1000.
   PubMed Web of Science ®Google Scholar
• Kolva E, Rosenfeld B, Brescia R, et al. Assessing decision-making capacity at end of life. Gen Hosp Psychiatry. 2014;36(4):392–397.
   PubMed Web of Science ®Google Scholar
• Leonard EW. Right to experimental treatment: FDA new drug approval, constitutional rights, and the public’s health. J Law, Med Ethics. 2009;37(2):269–279.
   PubMed Web of Science ®Google Scholar
• Right to try model legislation. Available from: https://goldwater-media.s3.amazonaws.com/cms_page_media/2016/1/5/GoldwaterInstituteRighttoTryModel.pdf
   Google Scholar
• Dennis B, Cha AE “Right to try” laws spur debate over dying patients’ access to experimental drugs. Washington Post. May 16, 2014
   Google Scholar
• H.R. 891, Gen. Assemb., Reg. Sess. (La. 2014) [“right-to-try” laws, manufactures can provide experimental medicines to terminally ill patients without FDA authorization].
   Google Scholar
• H.R. 1685, Gen. Assemb., Reg. Sess. (Mo. 2014) [“right-to-try” laws, manufactures can provide experimental medicines to terminally ill patients without FDA authorization].
   Google Scholar
• H.R. 1281, Gen. Assemb., Reg. Sess. (Colo. 2014) [“right-to-try” laws, manufactures can provide experimental medicines to terminally ill patients without FDA authorization].
   Google Scholar
• 21 U.S.C. § 823 [United States Code (USC) Controlled Substances Act].
   Google Scholar
• 21 C.F.R. § 1301.36 [Code of Federal Regulations, suspension or revocation of registration].
   Google Scholar
• Walker MJ, Rogers WA, Entwistle V. Ethical justifications for access to unapproved medical interventions: an argument for (limited) patient obligations. Am J Bioethics. 2014;14(11):3–15.
   PubMed Web of Science ®Google Scholar
• Chapman A. Proposal for patient obligations for access to unapproved medical interventions: both too much and not enough. Am J Bioethics. 2014;14(11):25–26.
   PubMed Web of Science ®Google Scholar
• Darrow JJ, Sarpatwari A, Avorn J, et al. Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med. 2015;372(3):279–286.
   PubMed Web of Science ®Google Scholar
• Magnus D. Compassion and research in compassionate use. Am J Bioethics. 2014;14(11):1–2.
   PubMed Web of Science ®Google Scholar
• Mackey TK, Schoenfeld VJ. Going “social” to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access. BMC Med. 2016;14:17.
   PubMed Web of Science ®Google Scholar
• Enhanced Clinical Trial Design Act of 2017. S. 1048, H.R. 2430.
   Google Scholar
• Kim ES, Bruinooge SS, Roberts S, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and friends of cancer research joint research statement. J Clin Oncol. 2017;35(33):3737–3744.
   PubMed Web of Science ®Google Scholar
• Jin S, Pazdur R, Sridhara R. Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015. J Clin Oncol. 2017;35(33):3745–3752.
   PubMed Web of Science ®Google Scholar
• Scoggins JF, Ramsey SD. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. J Natl Cancer Inst. 2010;102(17):1371.
   PubMedGoogle Scholar
• Korphaisarn K, Kopetz S. BRAF-directed therapy in metastatic colorectal cancer. Cancer J. 2016;22(3):175–178.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Eggermont AM, Schilsky RL. Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 2014;61–69.
   PubMedGoogle Scholar
• Tsimberidou AM, Hong DS, Ye Y, et al. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): an MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00002.
   PubMed Web of Science ®Google Scholar
• IMPACT 2. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02152254
   Google Scholar
• TAPUR Study. Available from: https://clinicaltrials.gov/ct2/show/NCT02693535
   Google Scholar
• The Drug Rediscovery Protocol (DRUP Trial) (DRUP). Available from: https://clinicaltrials.gov/show/NCT02925234
   Google Scholar
• Buzyn A, Blay JY, Hoog-Labouret N, et al. Equal access to innovative therapies and precision cancer care. Nat Rev Clin Oncol. 2016;13(6):385–393.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02034981?term=crizotinib&draw=1&rank=1
   Google Scholar
• Mullard A. PRIME time at the EMA. Nat Rev Drug Discov. 2017;16(4):226–228.
   PubMed Web of Science ®Google Scholar
• PRIME. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000660.jsp
   Google Scholar
• Em A. Cluster activities. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/general/general_content_000655.jsp&mid=WC0b01ac0580953d98.
   Google Scholar
• Dal Pan GJ, Arlett PR. The US Food and Drug Administration-European Medicines Agency collaboration in pharmacovigilance: common objectives and common challenges. Drug Saf. 2015;38(1):13–15.
   PubMed Web of Science ®Google Scholar